EUCTR2005-003139-38-Outside-EU/EEA进行中（未招募）不适用
Open-label extension study of CE1145 (Human pasteurized C1 esterase inhibitor concentrate) in subjects with congenital C1-INH deficiency and acute HAE attacks
ZLB Behring GmbH0 个研究点目标入组 57 人开始时间: 2015年2月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Documented congenital C1-INH deficiency
- •Acute HAE attack
- •Participation in the pivotal study CE1145_3001 (NCT00168103)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 7
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Acquired angioedema
- •Treatment with any other investigational drug besides CE1145 in the last 30 days before study entry
研究者
相似试验
进行中（未招募）
不适用
An open label extended study use of oral CEP-701 in patients with haematologic and non-haematologic malignancies who have participated in a clinical study of CEP-701 - NDHaematologic and non-haematologig malignancies in patients who have participated in clinical studies with CEP-701MedDRA version: 6.1Level: PTClassification code 10059034EUCTR2005-005542-39-ITCEPHALON EUROPE100
进行中（未招募）
不适用
An open-label extension study to Study 100185 to evaluate long-term saftey, efficacy and optimal dosing frequency of 750mg intravenous mepolizumab in subjects with hypereosinophilic syndrome.Hypereosinophilic syndrome (HES)MedDRA version: 7.0Level: LLTClassification code 10048643EUCTR2004-000930-35-BESmithKline Beecham plc84
招募中
3 期
Oral treprostinil open label study in subjects with pulmonary arterial hypertensioPrimary or secondary pulmonary arterial hypertension, other specified pulmonary heart diseasesI27.8I27.0I27.2RBR-9q7dy5Irmandade da Santa Casa de Misericórdia de Porto Alegre - ISCMPA
进行中（未招募）
不适用
An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disorder, characterized by gradual cognitive decline, abnormal behaviour, and personality changes.MedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2006-006490-24-SEeurochem Inc650
进行中（未招募）
不适用
An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disorder, characterized by gradual cognitive decline, abnormal behaviour, and personality changes.MedDRA version: 9.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2006-006490-24-FReurochem Inc650